Carlo Tanzi

Carlo has deep scientific and biotech industry experience that includes Investor Relations for established and emerging companies, program management for clinical and commercial stage therapeutics, and finance.

Carlo was previously Vice President, Investor Relations and Corporate Communications at Seres Therapeutics and a member of the leadership team. Earlier, Carlo worked at Biogen, including as Director of Investor Relations. Carlo's IR experience includes four product launches, numerous clinical read-outs, R&D investor days, IPO and follow-on financing, message development for novel technologies, driving sell-side coverage, and investor targeting.

Earlier in his career, Carlo was Program Management Lead at Biogen for Tecfidera and Tysabri where he gained experience in clinical development, product strategy, and commercialization. Carlo began his career as a healthcare management consultant at Health Advances.

Carlo currently serves as a Director with the Boston chapter of the National Investor Relations Institute (NIRI).